Project Grant R01CA293514
Award Date
4/21/25
Completion Date
3/31/30
Dollars Obligated
$642K
Federal Agency
National Cancer Institute
Awardee
Purdue University (YRXVL4JYCEF5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $447,831 to the University of Colorado-Denver for the development of chimeric antigen receptor (CAR) phagocytes to treat glioblastoma, a type of brain cancer. The project aims to advance novel immunotherapeutic approaches against high-grade gliomas, including glioblastoma multiforme (GBM), anaplastic astrocytoma, and diffuse intrinsic pontine glioma (DIPG) in pediatric patients. This...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of novel nanotherapeutics to overcome therapy resistance in high-grade gliomas (HGGs), including glioblastoma (GBM), using canine brain tumors as a spontaneous model. The $634,743 award will fund the following key activities over the 4-year project period starting July 1, 2024: 1) Development of a series of potent bisaminoquinoline derivative (BAQD) loaded...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
The National Cancer Institute (NCI) has awarded a $609,749 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of North Carolina at Chapel Hill (UNC-CH). The 5-year grant supports the development of a novel combinatorial therapy to improve treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products and services to be delivered under this grant include: Creating an injectable, biodegradable hydrogel...
The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial of CAR-T cells engineered to secrete a T cell-engaging antibody molecule (CARV3.TEAM-E cells) for the treatment of glioblastoma (GBM), a deadly brain tumor. The key products and services to be delivered under this $652,725 award, with a project...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Proton Bio, Inc. for a 12-month period from August 2024 to July 2025. The funding supports research to target the proton-sensing GPR68 receptor as a potential ferroptosis-based therapy for glioblastoma (GBM), the most common and deadly form of adult brain cancer. The key objectives are to: 1) define the in vitro pharmacological properties of lead ogremorphin compound candidates, 2)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $645,873 to The University of Texas MD Anderson Cancer Center to evaluate the feasibility and efficacy of a novel in vivo approach for generating chimeric antigen receptor (CAR) macrophages targeting the EGFR variant III protein expressed on glioblastoma cells. The proposed research aims to develop an innovative mRNA-based platform to produce CAR macrophages in vivo,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,271,780.00 to the University of Pittsburgh to develop small molecule adaptors for reprogramming a highly programmable universal chimeric antigen receptor (CAR) T cell therapy. The key products and services to be delivered include: Developing small molecule adaptors and combinations to target the universal CAR T cells to multiple antigens, including simultaneously targeting...
This STTR Phase I award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Immunoblue, LLC for $399,669 aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM). The key products and services to be delivered are: Generating potent and effective patient-derived GBM-specific T cells using a platform that applies Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) to GBM...